Login to Your Account



Cempra Adds $50.8M to Push Pivotal Solithromycin Program

By Jennifer Boggs
Managing Editor

Monday, June 17, 2013

On Thursday, Cempra Inc. disclosed a successful end-of-Phase II meeting with the FDA, citing only the need for additional funding to proceed with the planned Phase III trial testing intravenous (I.V.)-to-oral administration of macrolide antibiotic solithromycin in community-acquired bacterial pneumonia (CABP).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription